Did Whoopi Goldberg confirm she uses Mounjaro?

Yes. Goldberg confirmed her use of Mounjaro (tirzepatide) during on-air discussions on *The View*. She described it as a decision made with her doctor for weight management purposes.

Is Mounjaro the same as Ozempic?

No. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly. Ozempic contains semaglutide, a GLP-1-only agonist made by Novo Nordisk. Both promote weight loss, but tirzepatide has shown greater mean weight reduction in head-to-head-comparable trial data.

Is Mounjaro safe for women over 65?

Tirzepatide has been studied in adults across age groups, and subgroup analyses suggest efficacy is maintained in older patients. The primary concerns for women over 65 are lean muscle mass preservation, bone density monitoring, hydration status, and renal function. Close physician follow-up is essential. The FDA label does not contraindicate use based on age alone.

How much weight can you lose on Mounjaro?

In the SURMOUNT-1 clinical trial, participants on the 15 mg dose lost an average of 22.5% of body weight over 72 weeks. Individual results vary based on dose, adherence, diet, exercise, and baseline metabolic health. Lower doses (5 mg, 10 mg) produced mean losses of approximately 15% and 19.5%, respectively.

Does weight come back after stopping Mounjaro?

Available data suggest significant weight regain occurs after discontinuation. The SURMOUNT-4 trial showed that participants who switched from tirzepatide to placebo regained approximately two-thirds of lost weight over one year. This is consistent with the chronic-disease model of obesity: the underlying biology that drives weight gain does not resolve when the drug is stopped.

Whoopi Goldberg Transformation Timeline: Public Photos, Public Statements, and the Medical Context

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Whoopi Goldberg Transformation Timeline: Public Photos, Public Statements, and the Medical Context Image: HealthRX.com clinical image

At a glance

Medication confirmed: Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist
Public disclosure venue: The View (ABC daytime television)
Drug class: GLP-1 receptor agonist (dual-incretin)
FDA-approved indications: Type 2 diabetes (Mounjaro); chronic weight management (Zepbound, same molecule)
Relevance: One of the highest-profile Black women over 65 to confirm GLP-1 use publicly

The Public Record: What Whoopi Goldberg Has Said

Whoopi Goldberg confirmed her use of Mounjaro during segments on The View, the ABC daytime talk show she has co-hosted since 2007. During on-air conversations about the surge in GLP-1 prescriptions, Goldberg acknowledged that she had been prescribed tirzepatide for weight management.

Her disclosure was notable for its matter-of-fact tone. She did not frame the medication as a shortcut or a vanity choice. She described it as a medical decision made in consultation with her doctor, a framing the HealthRX.com Medical Team considers clinically responsible.

Goldberg has spoken publicly about weight-related health challenges for years. In prior interviews and on-air discussions, she has referenced joint pain, mobility concerns, and the difficulty of maintaining weight loss through diet and exercise alone as she aged. These statements, spread across multiple seasons of The View, establish a consistent public narrative: a woman managing the cumulative effects of aging, body composition changes, and the functional limitations that accompany them.

What Is Mounjaro (Tirzepatide)?

Mounjaro is the brand name for tirzepatide, manufactured by Eli Lilly. It received FDA approval in May 2022 for the treatment of type 2 diabetes mellitus.

Tirzepatide is not a standard GLP-1 receptor agonist. It is a dual-incretin agonist, meaning it activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism distinguishes it from semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda), which target GLP-1 alone.

The clinical significance of dual activation is measurable. In the SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, participants receiving the highest dose of tirzepatide (15 mg weekly) achieved a mean weight reduction of 22.5% over 72 weeks. For context, semaglutide 2.4 mg in the STEP 1 trial produced approximately 14.9% mean weight loss over 68 weeks.

Tirzepatide is administered as a once-weekly subcutaneous injection. Dosing starts at 2.5 mg and is titrated upward in 2.5 mg increments every four weeks, with a maximum dose of 15 mg. This slow titration exists to manage gastrointestinal side effects, which are the most common adverse events.

Why Age Matters: GLP-1 Use in Women Over 65

Goldberg was in her late 60s when she disclosed Mounjaro use. This detail is clinically relevant for several reasons.

Body composition shifts with age. After menopause, women experience accelerated loss of lean muscle mass (sarcopenia) and redistribution of adipose tissue toward visceral deposits. Research published in The Lancet Diabetes & Endocrinology has documented that visceral adiposity in postmenopausal women is independently associated with cardiovascular risk, insulin resistance, and systemic inflammation.

GLP-1 trials skew younger. The mean age in SURMOUNT-1 was approximately 45 years. While subgroup analyses have shown tirzepatide's efficacy holds across age brackets, older adults were a smaller fraction of enrolled participants. The SURMOUNT-2 trial included patients with type 2 diabetes (mean age ~54), which is closer to Goldberg's demographic but still younger.

Muscle preservation is the key concern. Weight loss in older adults, regardless of method, carries a risk of disproportionate lean mass loss. A 2021 study in JAMA Internal Medicine found that GLP-1-mediated weight loss includes both fat and muscle tissue. For a woman over 65, the HealthRX.com Medical Team emphasizes that resistance training and adequate protein intake (1.0 to 1.2 g/kg/day) are not optional adjuncts. They are essential to prevent sarcopenic complications like falls, fractures, and functional decline.

Kidney function requires monitoring. Age-related decline in glomerular filtration rate means that any medication cleared renally requires closer follow-up. Tirzepatide itself is not primarily renally cleared, but dehydration from GI side effects (nausea, vomiting, diarrhea) can precipitate acute kidney injury in older patients. The FDA prescribing information for Mounjaro includes warnings about renal monitoring in patients reporting severe GI symptoms.

The Side Effect Profile: What to Expect on Tirzepatide

The most commonly reported adverse events in clinical trials, relevant to anyone considering Mounjaro, include:

Nausea (reported in up to 31% of participants at 15 mg in SURMOUNT-1)
Diarrhea (up to 23%)
Constipation (up to 11%)
Vomiting (up to 9%)
Injection site reactions (mild, typically transient)

These GI effects tend to be most pronounced during dose escalation and diminish over time for most patients. The slow four-week titration schedule is designed specifically to reduce their severity.

More serious but less common risks include pancreatitis (patients are advised to report persistent, severe abdominal pain), gallbladder events (cholelithiasis risk increases with rapid weight loss), and a boxed warning regarding medullary thyroid carcinoma based on rodent studies. The relevance of the thyroid signal to humans remains uncertain, but tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

The HealthRX.com Medical Team Take

Whoopi Goldberg's public confirmation of Mounjaro use is significant for reasons that go beyond celebrity gossip.

She represents a population that is often excluded from the cultural conversation about GLP-1 medications: Black women over 65 with longstanding weight management challenges. The dominant media narrative around GLP-1 drugs has centered on younger Hollywood figures seeking cosmetic thinness. Goldberg's disclosure reframes the medication as what it clinically is, a therapeutic tool for metabolic health.

The HealthRX.com Medical Team notes three things about her case:

First, her age makes monitoring non-negotiable. Any prescriber working with a patient in her demographic should be tracking DEXA scans or body composition metrics to ensure fat loss is not coming at the expense of dangerous muscle depletion. Baseline and interval bone density screening is also warranted, as rapid weight loss in postmenopausal women can accelerate bone mineral density decline.

Second, her platform matters. The View reaches approximately 2.5 million daily viewers, many of them women over 50. When Goldberg discusses a prescription medication candidly and without shame, she reduces stigma for a demographic that CDC data shows has among the highest obesity prevalence rates in the United States (approximately 57% among non-Hispanic Black women). That normalization has public health value.

Third, the dual-incretin mechanism may offer specific advantages for her demographic. GIP receptor activation appears to have effects on bone metabolism and fat distribution that pure GLP-1 agonists do not. Early data, still being studied, suggest tirzepatide may produce more favorable body composition outcomes than semaglutide, with potentially less lean mass loss relative to total weight lost. This hypothesis requires confirmation in dedicated trials, but it is a plausible reason a prescriber might choose Mounjaro over Wegovy for an older female patient.

The bottom line: Goldberg's openness is clinically helpful. She is showing millions of women that seeking pharmaceutical support for weight management in your late 60s is a legitimate medical decision, not a concession. The HealthRX.com Medical Team agrees with that framing, with the caveat that the medication works best as one component of a comprehensive plan that includes strength training, nutritional optimization, and regular metabolic monitoring.

Frequently asked questions

›